The Lawyer Asia Pacific 150 is the only research report to provide a ranking of the top 100 independent local firms and top 50 global firms in the region. The report offers critical review of some of the fastest growing firms and their strategies, a country-by-country guide to leading legal advisers and legal services market trends, plus exclusive insight into the current business development opportunities in the Asia Pacific. Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
Freshfields Bruckhaus Deringer has reinstated itself as AstraZeneca's main UK firm for big M&A deals, scooping a key role on the company's $15.6bn (£7.78bn) purchase of MedImmune. Freshfields held off a chasing pack of City heavyweights, including Herbert Smith and Linklaters, which all have links with AstraZeneca. There is intense competition for AstraZeneca's corporate work as the company embarks on an acquisitive strategy to beef up its drug pipeline. Freshfields missed out on AstraZeneca's £702m purchase of Cambridge Antibody Technology last year due to client conflicts. Linklaters corporate partner Mark Stamp picked up that mandate in Freshfields' absence. Mayer Brown Rowe & Maw is advising AstraZeneca on the antitrust aspects of the MedImmune deal, led by EU and competition partner Frances Murphy. Latham & Watkins represented Merrill Lynch, which is acting as financial adviser to AstraZeneca. Dewey Ballantine is advising MedImmune.